dc.contributor.author | World Health Organization | |
dc.coverage.spatial | Geneva | en_US |
dc.date.accessioned | 2017-06-30T14:48:13Z | |
dc.date.available | 2017-06-30T14:48:13Z | |
dc.date.issued | 2004 | |
dc.identifier.uri | http://www.who.int/iris/handle/10665/255789 | |
dc.description | 13 p. | en_US |
dc.language.iso | en | en_US |
dc.publisher | World Health Organization | en_US |
dc.subject.mesh | Drugs, Essential | en_US |
dc.subject.mesh | Safety Management | en_US |
dc.subject.mesh | Drug Monitoring | en_US |
dc.subject.mesh | Pharmacovigilance | en_US |
dc.subject.mesh | Periodicals | en_US |
dc.title | WHO pharmaceuticals newsletter: 2004, No. 6 | en_US |
dc.type | Journal / periodical articles | en_US |
dc.description.startpage | 1 | en_US |
dc.description.endpage | 13 | en_US |
dc.relation.ispartofjournal | WHO pharmaceuticals newsletter | en_US |
dc.relation.issue | 4 | en_US |